Freenome and PCSC Announce $240 Million Merger Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy PCSC?
Source: PRnewswire
- Funding Commitment: Freenome secures $240 million through a PIPE led by Perceptive Advisors and RA Capital, which is expected to provide robust support for the commercialization of its blood-based cancer detection technology.
- Listing Plans: Following the merger, Freenome is set to list on Nasdaq under the ticker FRNM in the first half of 2026, which will create opportunities for market expansion and investor attraction.
- Capital Structure Optimization: The merger transaction is expected to provide Freenome with approximately $330 million, enhancing its competitiveness in the early cancer detection field and supporting future product development and market launch.
- Strategic Partnerships: Freenome's commercial partnerships with companies like Exact Sciences and Roche will support its global data accumulation and product improvement, further solidifying its position in the rapidly growing cancer detection market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PCSC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PCSC
About PCSC
Perceptive Capital Solutions Corp is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. It may pursue an acquisition opportunity in any business, industry, sector or geographical location. It intends to focus on industries that complement its management team’s background, and to capitalize on the ability of its management team to identify and acquire a business, focusing on the healthcare or healthcare-related industries. In particular, the Company is targeting North American or European companies in the life sciences and medical technology sectors. The Company neither engaged in any operations nor generated any revenues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perceptive Capital Solutions Stock Rises 20% Following Merger Agreement with Freenome
Stock Performance: Perceptive Capital Solutions Corp. (PCSC) saw a significant increase of 20.19%, rising $2.16 to $12.86 following the announcement of a merger with Freenome.
Merger Details: The business combination aims to create a publicly listed company focused on AI-enabled multi-omics blood-based multi-cancer detection, combining Perceptive's capital platform with Freenome's advanced cancer detection technology.
Market Reaction: The announcement led to unusually high trading volume for PCSC, reflecting investor optimism about the potential of the merged entity in the early detection and diagnostics market.
Stock Range: PCSC's stock has a 52-week trading range of approximately $4.10 to $15.20, indicating significant volatility and investor interest.
See More
Freenome and PCSC Announce $240 Million Merger Agreement
- Funding Commitment: Leading institutional investors have committed $240 million through a PIPE led by Perceptive Advisors and RA Capital, which is expected to provide ample capital for the combined company.
- Listing Plans: Upon completion of the merger, PCSC will be renamed Freenome, Inc. and listed on Nasdaq under the ticker FRNM, marking a significant milestone for the company entering public markets.
- Use of Funds: The transaction is expected to provide the combined company with approximately $330 million in funding, supporting Freenome's acceleration of its AI-driven multiomics platform development and plans to launch multiple blood-based cancer detection tests in 2026.
- Strategic Partnerships: Freenome will continue to leverage commercial partnerships with companies like Exact Sciences and Roche to expand its global data infrastructure, thereby driving future test improvements and pipeline expansion.
See More
Freenome and PCSC Announce $240 Million Merger Agreement
- Funding Commitment: Freenome secures $240 million through a PIPE led by Perceptive Advisors and RA Capital, which is expected to provide robust support for the commercialization of its blood-based cancer detection technology.
- Listing Plans: Following the merger, Freenome is set to list on Nasdaq under the ticker FRNM in the first half of 2026, which will create opportunities for market expansion and investor attraction.
- Capital Structure Optimization: The merger transaction is expected to provide Freenome with approximately $330 million, enhancing its competitiveness in the early cancer detection field and supporting future product development and market launch.
- Strategic Partnerships: Freenome's commercial partnerships with companies like Exact Sciences and Roche will support its global data accumulation and product improvement, further solidifying its position in the rapidly growing cancer detection market.
See More
Perceptive Capital Solutions Stock Rises 20% Following Merger Agreement with Freenome
Stock Performance: Perceptive Capital Solutions Corp. (PCSC) saw a significant increase of 20.19%, rising $2.16 to $12.86 following the announcement of a merger with Freenome.
Merger Details: The business combination aims to create a publicly listed company focused on AI-enabled multi-omics blood-based multi-cancer detection, combining Perceptive's capital platform with Freenome's advanced cancer detection technology.
Market Reaction: The announcement led to unusually high trading volume for PCSC, reflecting investor optimism about the potential of the merged entity in the early detection and diagnostics market.
Stock Range: PCSC's stock has a 52-week trading range of approximately $4.10 to $15.20, indicating significant volatility and investor interest.
See More
Freenome and PCSC Announce $240 Million Merger Agreement
- Funding Commitment: Leading institutional investors have committed $240 million through a PIPE led by Perceptive Advisors and RA Capital, which is expected to provide ample capital for the combined company.
- Listing Plans: Upon completion of the merger, PCSC will be renamed Freenome, Inc. and listed on Nasdaq under the ticker FRNM, marking a significant milestone for the company entering public markets.
- Use of Funds: The transaction is expected to provide the combined company with approximately $330 million in funding, supporting Freenome's acceleration of its AI-driven multiomics platform development and plans to launch multiple blood-based cancer detection tests in 2026.
- Strategic Partnerships: Freenome will continue to leverage commercial partnerships with companies like Exact Sciences and Roche to expand its global data infrastructure, thereby driving future test improvements and pipeline expansion.
See More
Freenome and PCSC Announce $240 Million Merger Agreement
- Funding Commitment: Freenome secures $240 million through a PIPE led by Perceptive Advisors and RA Capital, which is expected to provide robust support for the commercialization of its blood-based cancer detection technology.
- Listing Plans: Following the merger, Freenome is set to list on Nasdaq under the ticker FRNM in the first half of 2026, which will create opportunities for market expansion and investor attraction.
- Capital Structure Optimization: The merger transaction is expected to provide Freenome with approximately $330 million, enhancing its competitiveness in the early cancer detection field and supporting future product development and market launch.
- Strategic Partnerships: Freenome's commercial partnerships with companies like Exact Sciences and Roche will support its global data accumulation and product improvement, further solidifying its position in the rapidly growing cancer detection market.
See More
